Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$106.53 +2.0%	$102.22	$76.53 ▼ $131.49	$25.61B	1.29	950,228 shs	721,507 shs
BPMC Blueprint Medicines	$128.20 +0.1%	$104.75	$73.04 ▼ $128.34	$8.28B	0.84	1.26 million shs	4.51 million shs
ONC BeOne Medicines	$247.08 -2.3%	$245.59	$141.31 ▼ $287.88	$27.08B	0.3	301,400 shs	230,772 shs
TEVA Teva Pharmaceutical Industries	$16.97 -0.5%	$16.39	$12.47 ▼ $22.80	$19.46B	0.6	10.26 million shs	10.76 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-0.04%	+7.96%	+5.85%	+25.86%
BPMC Blueprint Medicines	0.00%	+0.19%	+26.31%	+34.56%	+23.00%
ONC BeOne Medicines	0.00%	-8.36%	+2.34%	-2.42%	+24,707,999,900.00%
TEVA Teva Pharmaceutical Industries	0.00%	-0.18%	+0.13%	+4.88%	+0.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.4598 of 5 stars	4.4	3.0	1.0	0.8	0.0
BPMC Blueprint Medicines	1.019 of 5 stars	2.1	2.0	2.0	0.8	0.6
ONC BeOne Medicines	2.2544 of 5 stars	3.5	0.0	2.2	1.7	0.6
TEVA Teva Pharmaceutical Industries	4.2897 of 5 stars	4.6	5.0	2.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.86	29.41% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.11% Downside
ONC BeOne Medicines	3.00	Buy	$319.00	29.11% Upside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	44.07% Upside

Current Analyst Ratings Breakdown

Latest BPMC, ONC, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.60	N/A	N/A	$87.61 per share	1.22
BPMC Blueprint Medicines	$508.82M	16.27	N/A	N/A	$4.70 per share	27.28
ONC BeOne Medicines	$3.81B	7.11	N/A	N/A	$34.10 per share	7.25
TEVA Teva Pharmaceutical Industries	$16.54B	1.18	$3.37 per share	5.04	$4.74 per share	3.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.23	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	348.00	N/A	-9.40%	-7.55%	-4.42%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.45	0.87	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest BPMC, ONC, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
BPMC Blueprint Medicines	1.01	2.80	2.75
ONC BeOne Medicines	0.05	1.96	1.71
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
BPMC Blueprint Medicines	N/A
ONC BeOne Medicines	48.55%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
BPMC Blueprint Medicines	4.21%
ONC BeOne Medicines	6.62%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

BPMC, ONC, BNTX, and TEVA Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Reduced by QRG Capital Management Inc.

June 20 at 4:11 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 18, 2025 | finanznachrichten.de

Teva and Fosun Pharma partner on early-stage oncology drug

June 18, 2025 | pharmatimes.com

Janney Montgomery Scott LLC Raises Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 18, 2025 | marketbeat.com

Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration

June 17, 2025 | csrwire.com

Teva Pharmaceutical Stock Surges Despite Recent Dip NYSE Composite

June 17, 2025 | kalkinemedia.com

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

June 17, 2025 | zacks.com

Teva to collaborate with Fosun Pharma for TEV-56278

June 17, 2025 | finance.yahoo.com

Teva and Fosun ink deal on TEV-56278 development

June 17, 2025 | thepharmaletter.com

GAMMA Investing LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 17, 2025 | marketbeat.com

Eliyahu Kalif Sells 55,775 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

June 16, 2025 | gurufocus.com

Handelsbanken Fonder AB Buys Shares of 15,792 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 16, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

June 16, 2025 | fool.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $24.44 Average Price Target from Brokerages

June 15, 2025 | americanbankingnews.com

Hennessy Advisors Inc. Sells 74,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 14, 2025 | marketbeat.com

SG Americas Securities LLC Has $5.19 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 13, 2025 | marketbeat.com

Americares, HDA honor Teva with Power of Partnership Award

June 12, 2025 | drugstorenews.com

Greenwood Capital Associates LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 12, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of "Buy" from Analysts

June 12, 2025 | marketbeat.com

Teva’s Next-Gen Trail Running Sandal Is Not Only Lighter — It’s Cheaper Too

June 11, 2025 | msn.com

Duquesne Family Office LLC Buys 5,882,350 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
Palantir Soars on Government Deals as Valuation Debate Lingers
By Chris Markoch | June 3, 2025
View Palantir Soars on Government Deals as Valuation Debate Lingers
Advance Auto Parts: Did Earnings Defuse Tariff Concerns?
By Gabriel Osorio-Mazilli | May 28, 2025
View Advance Auto Parts: Did Earnings Defuse Tariff Concerns?

BPMC, ONC, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$106.53 +2.13 (+2.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.60 -0.93 (-0.87%)

As of 06/20/2025 07:22 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Blueprint Medicines NASDAQ:BPMC

$128.20 +0.08 (+0.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$128.18 -0.01 (-0.01%)

As of 06/20/2025 08:00 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines NASDAQ:ONC

$247.08 -5.70 (-2.25%)

As of 06/20/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Teva Pharmaceutical Industries NYSE:TEVA

$16.97 -0.09 (-0.55%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$16.98 +0.01 (+0.05%)

As of 06/20/2025 06:29 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time